Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint

Loading news article.

Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint | WAPE

Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint

Article summary

Related companies

Comments —